Triomics, Inc.

Based in the US, Triomics, Inc. is a software company that specializes in transforming unstructured electronic health records into structured datasets for oncology workflows, utilizing advanced AI-driven solutions. Founded in 2021 and headquartered in New York, US, Triomics, Inc. focuses on developing AI technology for healthcare.

The company has successfully executed four deals with its most recent funding round being a Series B, where it raised USD 22 mn led by Battery Ventures. The founding team includes Hrituraj Singh, Roman Bieliaiev, and Sarim Khan, contributing to the company's innovative approach in health technology. The total amount raised by Triomics is USD 22 mn, achieving a current valuation of USD 99. 16 mn.

Triomics specializes in advanced AI-driven solutions that transform unstructured electronic health records (EHR) into structured, actionable datasets tailored for oncology workflows. The company's core product utilizes AI agents that analyze comprehensive patient records, including notes, reports, and faxes, to produce a structured view that enables healthcare teams to make informed decisions throughout a patient's care journey. Triomics' technology enhances clinical trial matching, enabling coordinators to efficiently identify candidates for trials, significantly reducing time spent on patient chart reviews. The platform serves a diverse client base, including NCI-designated cancer centers and community oncology practices across the United States, particularly in Connecticut and New York.

By integrating seamlessly with electronic medical records (EMR) systems such as Epic and OncoEMR, Triomics delivers valuable insights that streamline oncology workflows in the North American market. Triomics generates revenue through a subscription-based model, providing its AI platform to healthcare institutions and cancer centers that seek to improve clinical trial matching and patient management. In 2022, Triomics reported a revenue of USD 527,309. 10 with an EBITDA of USD -77,042.

30. The company engages in direct partnerships with oncology practices and hospitals, offering tailored solutions that enhance their existing workflows. Transactions typically involve annual or multi-year agreements, where clients pay for access to the Triomics platform, which includes features such as real-time trial matching and comprehensive patient data abstraction. These services are aimed at optimizing enrollment processes and improving patient outcomes in cancer care.

In May 2026, Triomics, Inc. completed a Series B funding round, raising USD 22 mn to accelerate adoption across health systems, oncology networks, and life sciences organizations. The company plans to grow its AI/engineering and forward-deployed teams while advancing its AI agents for clinical care and research. Upcoming product developments are focused on enhancing AI capabilities for better integration within oncology practices.

The funds will support expansion efforts, including targeting new geographic regions and markets, with specific strategies to reach a broader client base by 2027.